Daniel Nadler

Daniel Nadler is founder and CEO of OpenEvidence, an AI clinical decision-support platform for physicians valued at $12 billion as of January 2026. He previously founded Kensho Technologies in 2013 as a Harvard PhD student; Kensho was acquired by S&P Global for $550 million in 2018. He launched OpenEvidence in 2022 with co-founder Zack Ziegler to organize and surface peer-reviewed medical literature for clinicians. The company announced a $210 million round at a $3.5 billion valuation in 2025 and rolled out DeepConsult, an AI agent for physicians.